Issue link: https://viewer.e-digitaledition.com/i/882038
A FULLER PICTURE: The Transformative Potential of Total-body PET BY THOMAS CROCKER IMAGE COURTESY OF MARTIN JUDENHOFER, UC DAVIS PE T ¢ ONE OF THE MOST IMPORTANT TOOLS IN CLINICIANS' ARMAMENTARIUM FOR CANCER DIAGNOSIS, STAGING AND THER APY E VALUATION ¢ HA S A SIGNIFICANT LIMITATION: IT CAN SCAN ONLY A PORTION OF THE BODY AT A TIME. THAT MAY CHANGE SOON, WITH WIDE IMPLICATIONS FOR RESE ARCH AND CLINICAL PR ACTICE. T Y P I C A L LY C O M B I N E D W I T H C T, PET detect s t he photon sig na l f rom a radioactive tracer a nd its i nterac- tion with a ta rget orga n. The sca nner uses the sig na l to create images of the organ and related processes, such as its cells' absorption of glucose. How these cellula r processes unfold provides key clues to a ca ncer's presence a nd ex tent, a s wel l a s to its response to t herapy. PET can disting uish between lesions in ways CT a nd MR I ca nnot, according to Paula Jacobs, PhD, Associate Director of the Nationa l Ca ncer Institute (NCI) D iv i sion of Ca nc er T r e a t ment a nd Diag nosis Ca ncer Imag ing Prog ra m. "Neither [CT nor MR I] ca n tell if a lesion is metabolically active," Jacobs says. "One specific example is lung lesions. A lesion may look much the same on CT if it's benign, infectious or cancer, but it will appear quite diœerent on ... PET." In spite of its uti lit y a s a clinica l tool, PET is plagued by a fundamental problem, says Simon Cherry, PhD, a radi- ologist and Distinguished Professor of Biomedical Engineering at the University of California, Davis. "The way we currently collect our data [using PET] is very ine¢cient because the scanner only sees part of the body at any one time, but the radiation is all throughout the body, emitting away," he says. SPECIAL CLINICAL SECTION: ONCOLOGY 1 8

